Form 1 Financial Disclosure

Form Approved: OMB No. 0925-07533
Expiration Date: 07-31-2021

Collection of this information is authorized under 21 CFR: Part 54 [sections 2 and 4] and Part 312 [sections 53(c)(4) and 64(d)]. The use of this information is to disclose or certify
information concerning the financial interests of the clinical investigators associated with clinical studies. This information may be disclosed to sponsors of clinical trials, the applicable
Institutional Review Board, National Cancer Institute, Food and Drug Administration's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, and
the Department of Health and Human Services. Submission of this information is voluntary, however, in order to qualify to conduct studies in accordance with the relevant regulatory
requirements, you must complete all fields.
Public reporting burden for this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources,
gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond
to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information,
including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0753). Do not
return the completed form to this address.

CONFIDENTI AL
FINANCIAL DISCLOSURE FORM
The following confidential financial disclosure information is being collected for all investigators in accordance with 21
CFR: Part 54 and Part 312 [sections 53(c)(4) and 64(d)] . Any pharmaceutical or medical device
company that submits a marketing application for any drug, biologic product, or device is required to submit certain
information concerning the compensation to, and financial interests of, any clinical investigator participating in any
clinical study submitted in the marketing application. The Cancer Therapy Evaluation Program (CTEP) is collecting this
confidential information annually for all CTEP-registered investigators and sub-investigators.
*Please note that ‘You’ below refers to you, your spouse, or dependent children regarding any of the following
disclosable financial arrangements.

Yes

No

Do You* currently have or have you at any time in the past year had any financial arrangement
with a pharmaceutical, biologic, or medical device company whereby the value of the
compensation could be influenced by study outcomes?

Yes

No

Do You* currently have or have you at any time in the past year had any payments made to you
or to your institution from a pharmaceutical, biologic, or medical device company, such as a
grant to fund ongoing research, compensation in the form of equipment, retainer for ongoing
consultation, or honoraria?

Yes

No

Do You* currently have or have you at any time in the past year had any proprietary interest in
any drug, biologic product, or medical device?

Yes

No

Do You* currently have or have you at any time in the past year had any equity interest in a
pharmaceutical, biologic, or medical device company?

If you answered “Yes” to any of the questions above, please provide the name of the pharmaceutical, biologic, or
medical device company or companies with whom the financial arrangement exists.
PHARMACEUTICAL, BIOLOGIC, OR MEDICAL DEVICE COMPANY OR COMPANIES
CTEP Company Code

Company Name

Company Address

ACKNOWLEDGEMENT



AGREEMENT: By signing this Electronic Signature Acknowledgment Form, I attest to the accuracy and integrity of this document and agree
that my electronic signature is the legally binding equivalent to my handwritten signature. Whenever I execute an electronic signature, it has
the same validity and meaning as my handwritten signature. I will not, at any time in the future, repudiate the meaning of my electronic
signature or claim that my electronic signature is not legally binding.
The complete NCI registration documents will be maintained by the Pharmaceutical Management Branch, CTEP as part of your confidential
investigator registration file and will be kept private, under the Privacy Act. Information collected on this form will only be provided (1) to a
company which has an agreement (e.g., a Clinical Trials Agreement [CTA] or a Cooperative Research and Development Agreement
[CRADA]) with CTEP if CTEP is notified that a licensing application is being prepared by that company, (2) to a Network or Group of which
you are a member if CTEP is notified that a clinical trial is being developed by that Network or Group and a company with whom you have
indicated a financial arrangement, or (3) the Food and Drug Administration. You may be contacted in the future by a pharmaceutical
company representative or by your Network or Group administrative staff for additional information.

(Rev. 31-JUL-2018)

PAGE 1 of 2

SIGNATURE

DATE

This is an electronic signature and is the legally binding equivalent to a handwritten signature.

(WARNING: A willfully false statement is a criminal offense. U.S.C. Title 18, Sec.1001.)

(Rev. 31-JUL-2018)

PAGE 2 of 2